SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LemurHouse who wrote (412)6/17/2000 3:02:00 PM
From: sam  Read Replies (1) of 656
 
Novel Agents Are Transforming the Rheumatoid Arthritis Market -- A Decision Resources Study Evaluates Their Therapeutic and Commercial Potential

...The most revolutionary change in RA treatment in the United States is the recent introduction of biological agents that inhibit the activity of tumor necrosis factor-alpha: etanercept (Immunex/American Home Products' Enbrel) and infliximab (Centocor/Johnson & Johnson's Remicade). Clinical data have demonstrated that these drugs are far more effective than methotrexate, the current gold standard. Because of exorbitant costs and lingering safety concerns, these agents are reserved for patients with active RA who are refractory to methotrexate. However, in April 2000, an advisory committee to the FDA recommended an expanded label for etanercept to include patients withearly active RA. We expect that tumor necrosis factor-alpha inhibitors will remain the most prominent new drug class for at least five years....

We estimate that sales of RA therapies in the seven major markets were almost $1.5 billion in 1999. We believe this market will grow considerably over our ten-year study period, achieving total sales of $6.6 billion by 2009. The majority of this growth will be driven by continued adoption of biological agents and novel cytokine modulators that are likely to reach the market by 2004. We estimate the biological segment of the RA marketplace will alone be worth approximately $4.5 billion in 2009.

prnewswire.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News